This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study to Compare the Pharmacokinetic Profiles of DW224aa and DW224a

This study has been completed.
Dong Wha Pharmaceutical Co. Ltd.
Information provided by:
Seoul National University Hospital Identifier:
First received: April 20, 2011
Last updated: July 15, 2011
Last verified: July 2011
The purpose of this study is to compare and explore pharmacokinetics of zabofloxacin, the main component of DW224aa(Test drug) and DW224a(Reference drug).

Condition Intervention Phase
Healthy Drug: Experimental DW224aa Drug: Experimental DW224a Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Official Title: Clinical Trial to Compare the Pharmacokinetic Profiles of DW224aa (Aspartate) Tablet and DW224a (Hydrochloride) Capsule After a Single Oral Administration in Healthy Male Volunteers

Further study details as provided by Seoul National University Hospital:

Primary Outcome Measures:
  • Cmax of zabofloxacin in plasma [ Time Frame: Up to 48 ]
  • AUClast of zabofloxacin in plasma [ Time Frame: Up to 48 ]

Secondary Outcome Measures:
  • Tmax of zabofloxacin in plasma [ Time Frame: Up to 48h ]
  • terminal half-life (t1/2) of zabofloxacin in plasma [ Time Frame: Up to 48h ]
  • CL/F of zabofloxacin in plasma [ Time Frame: Up to 48h ]

Estimated Enrollment: 32
Study Start Date: April 2011
Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: DW224aa
DW224aa given by oral administration
Drug: Experimental DW224aa
DW224aa tablet, single dose
Active Comparator: DW224a
DW224aa given by oral administration
Drug: Experimental DW224a
DW224a capsule, single dose


Ages Eligible for Study:   20 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • a healthy adult male within the range of 20 to 45 years old at the time of screening
  • one with weight of more than 55kg, in the range of IBW 20%

    • IBW(kg)={height(cm)-100}*0.9
  • one who understood completely about this study after the detailed explanation is given, decided to volunteer and gave written informed consent to participate in study in compliance with the requirement of the entire protocol.

Exclusion Criteria:

  • one with clinically significant disease in liver, kidney, nerve system, respiratory system, endocrine system, blood, tumor, urinary system, cardiovascular system, mental disease or with medical history
  • one with gastrointestinal disease or with gastrointestinal surgical history which can affect the absorption of the investigational drug.
  • one who is allergic or has clinically significant allergic history to the quinolone antibiotics, or to other drugs(Aspirin, antibiotics, etc)
  • one who shows the following result in clinical laboratory test: AST,ALT>1.25 times of the upper limit of normal range
  • one who has confirmed positive at serological tests (HBs antigen, HCV antibody and HIV antibody)
  • one who has drug abuse history or positive result at urine screening tests (cannabinoid, opioid, amphetamine, cocaine, barbiturate, benzodiazepine)
  • one who has taken any prescribed drugs, herbal agents or crude drugs within 2 weeks before study drug administration, or who has taken any over-the-counter (OTC) drugs or vitamins (Investigators will determine his eligibility by considering the effect of the drug on his safety or pharmacokinetic results in case other inclusion/exclusion criteria is satisfied.)
  • one who has participated in other clinical study within 2 months before study drug administration
  • one who donated whole blood within 2 months or component blood within 1 month or who are donated within 1 month before the treatment
  • one who drank Over 21 units/week of alcohol or subjects who would not be able to stop drinking alcohol during the hospitalization
  • one who are Heavy smoker more than 10 cigarettes/day within 3 months prior to screening or subjects who would not be able to stop smoking during the hospitalization
  • one who had a beverage containing caffeine, drank alcohol, or smoked within 48hrs before the hospitalization or who had a beverage containing grapefruits during the hospitalization
  • one with clinically significant observations considered as unsuitable based on medical judgment by investigators
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01341249

Korea, Republic of
Clinical Trials Center, Seoul National University Hospital
Seoul, Korea, Republic of
Sponsors and Collaborators
Seoul National University Hospital
Dong Wha Pharmaceutical Co. Ltd.
Principal Investigator: Kyung Sang Yu, MD, PhD Seoul National University Hospital
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Chang-Soo Cho, DONG WHA PHARMACEUTICAL CO., LTD Identifier: NCT01341249     History of Changes
Other Study ID Numbers: SNUCPT11_DW224aa
Study First Received: April 20, 2011
Last Updated: July 15, 2011

Additional relevant MeSH terms:
Anti-Bacterial Agents
Anti-Infective Agents
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on August 18, 2017